| Primary |
| Hyperthermia Malignant |
66.7% |
| Muscle Spasticity |
10.3% |
| Blood Creatine Phosphokinase Increased |
7.7% |
| Anaesthesia |
5.1% |
| Analgesic Effect |
2.6% |
| Hypertension |
2.6% |
| Neuroleptic Malignant Syndrome |
2.6% |
| Schizoaffective Disorder |
2.6% |
|
| Respiratory Failure |
16.1% |
| Muscular Weakness |
12.9% |
| Cardiac Disorder |
6.5% |
| Dysphagia |
6.5% |
| Myelodysplastic Syndrome |
6.5% |
| Organ Failure |
6.5% |
| Acute Respiratory Failure |
3.2% |
| Altered State Of Consciousness |
3.2% |
| Aspiration |
3.2% |
| Cardiac Output Decreased |
3.2% |
| Cerebrovascular Accident |
3.2% |
| Disseminated Intravascular Coagulation |
3.2% |
| Eye Disorder |
3.2% |
| Gamma-glutamyltransferase Increased |
3.2% |
| Hepatic Enzyme Increased |
3.2% |
| Hepatic Function Abnormal |
3.2% |
| Hepatic Trauma |
3.2% |
| Hyperkalaemia |
3.2% |
| Hypotension |
3.2% |
| Oedema Peripheral |
3.2% |
|
| Secondary |
| Drug Use For Unknown Indication |
26.6% |
| Muscle Spasticity |
13.6% |
| Depression |
8.5% |
| Anaesthesia |
7.3% |
| Tachyarrhythmia |
6.2% |
| Tendon Rupture |
4.0% |
| Type 2 Diabetes Mellitus |
4.0% |
| Gastritis Prophylaxis |
3.4% |
| Product Used For Unknown Indication |
3.4% |
| Epilepsy |
2.8% |
| Neuroleptic Malignant Syndrome |
2.8% |
| Bone Sarcoma |
2.3% |
| Cardiovascular Event Prophylaxis |
2.3% |
| Multiple Sclerosis |
2.3% |
| Musculoskeletal Stiffness |
2.3% |
| Phantom Pain |
2.3% |
| Hypertension |
1.7% |
| Hyperthermia Malignant |
1.7% |
| Prophylaxis |
1.7% |
| Agitation |
1.1% |
|
| Hyponatraemia |
11.9% |
| Mechanical Ventilation |
9.5% |
| Neuroleptic Malignant Syndrome |
9.5% |
| Vaginal Haemorrhage |
9.5% |
| Rhabdomyolysis |
7.1% |
| Brain Oedema |
4.8% |
| Renal Failure |
4.8% |
| Respiratory Failure |
4.8% |
| Subarachnoid Haemorrhage |
4.8% |
| Thrombocytopenia |
4.8% |
| Torticollis |
4.8% |
| Ventricular Fibrillation |
4.8% |
| Hyperthermia Malignant |
2.4% |
| Myoglobinuria |
2.4% |
| Pyrexia |
2.4% |
| Rash |
2.4% |
| Sinus Arrhythmia |
2.4% |
| Tendon Injury |
2.4% |
| Therapy Cessation |
2.4% |
| Venous Thrombosis |
2.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
22.9% |
| Depression |
11.9% |
| Emphysema |
6.6% |
| Gaucher's Disease |
6.2% |
| Product Used For Unknown Indication |
6.2% |
| Atrial Fibrillation |
5.0% |
| Insomnia |
4.6% |
| Multiple Sclerosis |
4.0% |
| Cerebral Palsy |
3.8% |
| Prophylaxis |
3.8% |
| Hypotonia |
3.5% |
| Gastrostomy |
3.2% |
| Infection Prophylaxis |
3.2% |
| Torticollis |
2.9% |
| Acute Lymphocytic Leukaemia |
2.4% |
| Muscle Spasticity |
2.4% |
| Arrhythmia |
2.2% |
| Muscle Spasms |
2.1% |
| Bone Marrow Conditioning Regimen |
1.5% |
| Sedation |
1.5% |
|
| Neuroleptic Malignant Syndrome |
17.6% |
| Tonic Convulsion |
12.7% |
| Urinary Tract Infection |
7.8% |
| Wheezing |
7.8% |
| Somnolence |
6.9% |
| Status Epilepticus |
4.9% |
| Withdrawal Syndrome |
4.9% |
| Respiratory Failure |
3.9% |
| Tachycardia |
3.9% |
| Vomiting |
3.9% |
| Blood Sodium Decreased |
2.9% |
| Blood Sodium Increased |
2.9% |
| Cardio-respiratory Arrest |
2.9% |
| Femoral Neck Fracture |
2.9% |
| Pneumonia |
2.9% |
| Tremor |
2.9% |
| Anaemia |
2.0% |
| Depression Suicidal |
2.0% |
| Fall |
2.0% |
| Fistula |
2.0% |
|
| Interacting |
| Hypertension |
26.3% |
| Neuroleptic Malignant Syndrome |
26.3% |
| Schizoaffective Disorder |
26.3% |
| Diabetes Mellitus |
21.1% |
|
| Ventricular Fibrillation |
100.0% |
|
